Brief: Bioversys Expects Total Operating Loss Of CHF 40-45 Mln For FY2026
18/03/2026 07:40
March 18 (Reuters) - BioVersys AG BIOV.S: BIOVERSYS REPORTS CORPORATE HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FULL YEAR 2025 BIOVERSYS AG - EXPECTS TOTAL OPERATING LOSS OF CHF 40-45 MILLION FOR FY2026 Source text: ID:nGNX1Qgcz3 Further company coverage: BIOV.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioVersys AG
See all newsBrief: Bioversys Expects Total Operating Loss Of CHF 40-45 Mln For FY2026
RCS - Bio Versys AG - BioVersys and partners’
Brief: BioVersys Announces BV100 Phase 3 Initiation And Provides Business Update
Brief: Bioversys Says Patent Claims For Its BV100 Drug Candidate Have Been Granted In China
UBS, Stifel start coverage of BioVersys with 'buy;' shares climb